AR024171A1 - Metodos y compuestos para el tratamiento de enfermedades mediadas por el sistema inmunitario mediante el uso de mycobacterium vaccae - Google Patents

Metodos y compuestos para el tratamiento de enfermedades mediadas por el sistema inmunitario mediante el uso de mycobacterium vaccae

Info

Publication number
AR024171A1
AR024171A1 ARP000102691A ARP000102691A AR024171A1 AR 024171 A1 AR024171 A1 AR 024171A1 AR P000102691 A ARP000102691 A AR P000102691A AR P000102691 A ARP000102691 A AR P000102691A AR 024171 A1 AR024171 A1 AR 024171A1
Authority
AR
Argentina
Prior art keywords
methods
treatment
compounds
immune system
diseases mediated
Prior art date
Application number
ARP000102691A
Other languages
English (en)
Original Assignee
Genesis Res & Dev Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesis Res & Dev Corp Ltd filed Critical Genesis Res & Dev Corp Ltd
Publication of AR024171A1 publication Critical patent/AR024171A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se presentan métodos para la prevencion y el tratamiento de trastornos, incluyendo trastornos del sistema respiratorio como la infeccion con micobacteriastales como M.tuberculosis o M.avium, sarcoidosis, asma, rinitis alérgica y cánceres de pulmon,m étodos que comprenden la administracion de una composicion quecontiene por lo menos un derivado de células de M.vaccae deslipidizada y desglupolipidizada.
ARP000102691A 1999-06-02 2000-05-31 Metodos y compuestos para el tratamiento de enfermedades mediadas por el sistema inmunitario mediante el uso de mycobacterium vaccae AR024171A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13711299P 1999-06-02 1999-06-02
US09/449,013 US6350457B1 (en) 1999-06-02 1999-11-24 Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae

Publications (1)

Publication Number Publication Date
AR024171A1 true AR024171A1 (es) 2002-09-04

Family

ID=26834939

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102691A AR024171A1 (es) 1999-06-02 2000-05-31 Metodos y compuestos para el tratamiento de enfermedades mediadas por el sistema inmunitario mediante el uso de mycobacterium vaccae

Country Status (11)

Country Link
US (2) US6350457B1 (es)
EP (1) EP1181051A4 (es)
JP (1) JP2003501400A (es)
KR (1) KR20020021375A (es)
CN (1) CN1162181C (es)
AR (1) AR024171A1 (es)
AU (1) AU779163B2 (es)
BR (1) BR0011239A (es)
CA (1) CA2374256A1 (es)
HK (1) HK1048261A1 (es)
WO (1) WO2000074715A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569436B1 (en) 1998-10-05 2003-05-27 The Malaghan Institute Of Medical Research Method of using a vaccine
WO2001057534A2 (en) * 2000-02-04 2001-08-09 Bioseek Compositions and methods for reducing autoimmunity
US20030147861A1 (en) * 2001-07-26 2003-08-07 Genesis Research And Development Corporation Limited Compounds and methods for the modulation of immune responses
SI1461054T1 (sl) 2001-12-11 2010-09-30 Pasteur Institut Pripravki grampozitivnih bakterij za zdravljenje bolezni ki obsegajo imunsko disregulacijo
JP2010506908A (ja) * 2006-10-20 2010-03-04 スーヨル キム， グルコサミンまたはグルコサミン誘導体を含むアトピー性皮膚炎治療用組成物およびこれらを使用しアトピー性皮膚炎を治療する方法
EP2292260A1 (en) * 2009-08-13 2011-03-09 Institut Pasteur Use of mycobacterium bovis BCG killed by extended freeze drying (EFD) for preventing or treating atherosclerosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326B1 (es) 1971-11-19 1975-02-07 Anvar
NL7308450A (es) 1972-06-20 1973-12-27
US4579945A (en) 1982-04-29 1986-04-01 Ribi Immunochem Research, Inc. Purification of trehalose dimycolates
US4503048A (en) 1982-06-30 1985-03-05 Ribi Immunochem Research, Inc. Pyridine soluble extract of a microorganism
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
AU638970B2 (en) 1989-01-23 1993-07-15 Auspharm International Limited Vaccine composition
GB9219425D0 (en) 1992-09-14 1992-10-28 Univ London Therapeutic agent and its use
GB8917256D0 (en) 1989-07-28 1989-09-13 Univ London Biological preparation and its use
GB8919321D0 (en) 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
ATE154759T1 (de) 1990-11-08 1997-07-15 Univ London Mycobacterium als adjuvans für antigene
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
GB9203814D0 (en) 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
GB9406301D0 (en) 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
AUPO359396A0 (en) 1996-11-13 1996-12-05 Amrad Operations Pty. Limited A method of treatment and pharmaceutical compositions useful for same
CA2315539A1 (en) * 1997-12-23 1999-07-01 Genesis Research & Development Corporation Limited Compositions derived from mycobacterium vaccae and methods for their use

Also Published As

Publication number Publication date
EP1181051A1 (en) 2002-02-27
US6350457B1 (en) 2002-02-26
CN1371285A (zh) 2002-09-25
BR0011239A (pt) 2002-04-02
AU779163B2 (en) 2005-01-06
AU5257900A (en) 2000-12-28
CN1162181C (zh) 2004-08-18
JP2003501400A (ja) 2003-01-14
WO2000074715A1 (en) 2000-12-14
EP1181051A4 (en) 2004-09-15
HK1048261A1 (zh) 2003-03-28
CA2374256A1 (en) 2000-12-14
US6723327B1 (en) 2004-04-20
KR20020021375A (ko) 2002-03-20

Similar Documents

Publication Publication Date Title
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
AR106800A1 (es) Composiciones que comprenden cepas bacterianas
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
EP1784639A4 (en) PROCESS FOR PREPARING FREEZERTED BLOOD PLATES, FLUIDIZED BLOOD PLATES, COMPOSITIONS AND USE METHOD
CY1118006T1 (el) Χρηση γαλακτοβακιλλων για την αγωγη ιικων λοιμωξεων
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CR10582A (es) Metodos para tratar canceres usando formas poliformicas de 3-(-4-amino-1,3, dihidro-isoindol-2-il)-piperidina-2,6 dione (divisional exp. 8146)
CY1117290T1 (el) Εμβολιο φυματιωσης και μεθοδος χρησης αυτου
BRPI0607351A2 (pt) métodos para tratamento de linfomas empregando uma combinação de agente quimioterapêutico e il-2 e opcionalmente um anticorpo anti-cd20
BRPI0507250A (pt) combinações para tratar desordens do snc
NO20055474L (no) Mediatorer av revers kolesteroltransport for behandling av hyperkolesterolemi
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
BR112019005536A2 (pt) microrganismos oxidantes de amônia para uso e entrega para o sistema intranasal
BR112015025025A2 (pt) composições terapêuticas e usos das mesmas
Balaji et al. Revised ciprofloxacin breakpoints for Salmonella Typhi: its implications in India
BR112015024621A8 (pt) usos de dose unitária de unidades formadoras de colônia de c. novyi, composição farmacêutica compreendendo a referida dose unitária, kit para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano e dose unitária de unidades formadoras de colônia de c. novyi
AR032989A1 (es) Una composicion farmaceutica util para el tratamiento del cancer
DE69841200D1 (de) Oxalate-abbauende mikroorganismen oder oxalate-abbauende enzyme zur verhütung der oxalate-verwandten krankheiten
AR024171A1 (es) Metodos y compuestos para el tratamiento de enfermedades mediadas por el sistema inmunitario mediante el uso de mycobacterium vaccae
UY28313A1 (es) Nonadepsipeptidos acilados
CR20230164A (es) Compuestos fosfolípidos y usos de estos
PT1358177E (pt) Tratamento de desordens afectivas atraves da accao combinada de um agonista do receptor nicotinico e uma substancia manoaminergica
MX2021005421A (es) Macrólidos de 13 miembros con sustitución cíclica en c10 y usos de los mismos.